Combination of Interleukin-15 With a STING Agonist, ADU-S100 Analog: A Potential Immunotherapy for Prostate Cancer

Combination of Interleukin-15 With a STING Agonist, ADU-S100 Analog: A Potential Immunotherapy for Prostate Cancer

Prostate cancer is the second most commonly diagnosed cancer in men with mortality rates, overtaking those for breast cancer in the last 2 years in the UK. Despite advances in prostate cancer treatments, over 25% of men do not survive over 5 years with advanced disease. Due to the success of immunot...

Full description

Bibliographic Details
Main Authors: Ana M. Esteves, Efthymia Papaevangelou, Prokar Dasgupta, Christine Galustian
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Oncology
Subjects:
Interleukin-15
STING agonist
prostate cancer
NK cells
cytotoxicity
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.621550/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.621550/full

Similar Items